Oxurion NV to Present at 2019 Biotech ShowcaseTM Conference

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview at the 2019 Biotech ShowcaseTM conference at 3:30 p.m. PST on Tuesday, Jan. 8, 2019 at the Hilton San Francisco Union Square.

Additionally, Dr. De Haes will participate in a CEO power breakfast roundtable as a panellist at 7 a.m. PST on Wednesday, Jan. 9, 2019 at the Sir Francis Drake Hotel in San Francisco. The panel will feature life sciences executives examining topics including drug innovation and strategic partnering moderated by FierceBiotech editor, Amirah Al Idrus. Please fill out the contact form to RSVP for the event.


Furthermore, Oxurion's management team will also hold one-on-one meetings with institutional investors and analysts Jan. 7-9 in San Francisco. Institutional investors and analysts can register and request meetings through the online system.


Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company focused on transforming treatments to preserve vision in patients with diseases affecting the back of the eye. The company is currently developing a competitive pipeline of disease-modifying drug candidates for diabetic eye disease, a leading cause of blindness of people of working age worldwide.

Oxurion's most advanced drug candidate is THR-317, a PlGF inhibitor for the treatment of diabetic macular edema (DME), which is currently in a Phase 2 study in combination with Lucentis®. THR-317 is also being evaluated in a Phase 2 study for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare retinal disease that affects the macula and can lead to vision loss.

Oxurion has two further pipeline candidates, THR-149, a plasma kallikrein inhibitor being developed for the treatment of DME; and THR-687, a pan-RGD integrin antagonist in development for the treatment of diabetic retinopathy and DME. Both THR-149 and THR-687 are in Phase 1 clinical studies.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

More information is available at www.oxurion.com.



Interested in a regular update of the Life Sciences and biotech sector in Flanders?